TCRX · TScan Therapeutics, Inc.
$0.74
-0.03 (-3.84%)
At close · Jul 29
Market Cap
$48.46M
Shares
65.35M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.77
Open$0.77
Day$0.73–0.77
52W$0.73–2.57
Avg vol 30d784K
Short int1.4M · 2.1% float · 1.2d
Short vol71%
Last earningsMay 6, 2025
DataJul 2021–Jul 2026
Filing10-Q · May 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−33%
below
Price vs 50-day avg
−20%
below
RSI (14)
36
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−22%
trailing
6-month return
−22%
trailing
YTD return
−23%
this year
Relative strength
−30%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 60 funds reported for Jun 30 · net +205.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.12% of float · ▲ +95.5% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+267%
Y/Y
EPS growth
+12%
Y/Y
Free cash flow
$-139.7M
Balance sheet
$116.5M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
11.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−33%
Bearish
Price vs 50-day avg
−20%
Bearish
RSI (14)
36
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
4 of 60 funds reported for Jun 30 · net +205.6K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.12% of float · ▲ +95.5% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
60 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 2%
52-wk high $3
vs 200-day avg -33%
vs 50-day avg -20%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TCRX
this stock
TScan Therapeutics, Inc.
|
$48.46M | -22.6% | -86.6% | — | 2.1% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TCRX | -17.7% | -21.8% | -22.3% | -21.0% | -22.6% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -16.7% | -21.8% | -29.7% | -20.2% | -31.2% |